Traders should monitor the upcoming ELPIS II trial results for HLHS in Q3 2026, the company's ability to maintain Nasdaq listing, and whether it can secure additional funding. The stock faces significant downside risk due to financial instability and regulatory compliance issues.
LGVN drugs
LGVN drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 13 $1.12entry
- T+1 · 7mo ago 0.00%α −1.21% · $1.12
- T+5 · 7mo ago −7.14%α −10.44% · $1.04
- T+20 · 6mo ago −25.18%α −32.91% · $0.8380
- T+60 · 4mo ago −42.59%α −51.51% · $0.6430
How similar events traded
Executive Summary
Longeveron Inc. (LGVN) is registering 30.9 million shares for resale by selling stockholders, including shares from a recent private placement and convertible preferred stock. The company is a clinical-stage biotech advancing its lead therapy laromestrocel for rare diseases, but faces going concern risks and Nasdaq listing compliance issues. While it recently raised $15.9 million, it needs additional funding and has a weak cash position.
Key Facts
- Company is registering 30,865,385 shares for resale by selling stockholders, including 6.0 million shares issued and 22.8 million shares issuable upon conversion of preferred stock
- Laromestrocel is in clinical development for Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease, pediatric dilated cardiomyopathy, and aging-related frailty
- Company received a going concern opinion from auditors due to working capital deficiency, stockholders' deficit, and recurring losses
- Nasdaq has issued a minimum bid price deficiency notice, and the company has until September 21, 2026 to regain compliance
- Recent private placement raised approximately $15.9 million in gross proceeds before fees
- The company plans to use any proceeds from warrant exercises for clinical development and working capital
Financial Impact
Up to $1.3 million if all placement agent warrants are exercised, but no proceeds to company from the share resale registration
Risk Factors
- Going concern risk due to working capital deficiency and recurring losses
- Nasdaq delisting risk if minimum bid price requirement is not met by September 2026
- Significant dilution from outstanding warrants and convertible preferred stock
- Dependence on successful clinical trial outcomes for survival
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001213900-26-042461 |
| Document: ea028582701ex5-1.htm | 0001213900-26-042461 |
| Document: ea028582701ex-fee.htm | 0001213900-26-042461 |
| Document: ea028582701ex23-2.htm | 0001213900-26-042461 |
| Document: ea028582701ex23-1.htm | 0001213900-26-042461 |
| Document: 0001213900-26-042461-index-headers.html | 0001213900-26-042461 |
| Document: 0001213900-26-042461-index.html | 0001213900-26-042461 |
| Document: 0001213900-26-042461.txt | 0001213900-26-042461 |
Track record
22 reports on LGVN
3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +44.65% at T+20 after the Sep 16, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.53 Now $2.14 +15.42% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $2.49 Now $2.14 −14.06% settles Feb 11
- Nov 12, 20264d ago 8-K Bearish 7/10 No price data
- Nov 12, 20264d ago Press Release Bearish 6/10 Entry $2.49 Now $2.14 +14.06% settles Feb 11
- Nov 5, 202611d ago SC 13G/A Bearish 5/10 Entry $1.81 Now $2.14 −18.23% settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 2/10 Entry $1.81 Now $2.14 +18.23% settles Feb 4
- Oct 26, 202621d ago 8-K Neutral 5/10 Entry $1.73 Now $2.14 +23.70% settles Jan 25
- Oct 26, 202621d ago Press Release Mixed 6/10 Entry $1.61 Now $2.14 +33.33% settles Jan 22
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $1.50 Now $2.14 +42.67% settles Jan 12
- Sep 16, 20268w ago Press Release Bearish 7/10 Entry $2.71 Now $2.14 +21.03% settles Dec 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers